Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 6/2018

25.10.2018 | B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)

Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies

verfasst von: Helen Ma, Ahmed Sawas

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review is about the antibody-drug conjugate (ADC), a form of drug delivery consisting of a monoclonal antibody, linker, and cytotoxic payload. We summarize the history of ADC development, highlighting the three FDA-approved ADCs currently available.

Recent Findings

Gemtuzumab ozogamicin is a CD33-targeted ADC linked to calicheamicin. It is approved for CD33+ AML in the first line or the relapsed or refractory (R/R) setting. Brentuximab vedotin is a CD30-targeted ADC bound to MMAE. It is approved for the treatment of certain R/R CD30+ lymphomas. Recently, it has been approved for first line therapy with chemotherapy in advanced HL. Inotuzumab ozogamicin is a CD22-directed ADC attached to calicheamicin indicated for the treatment of adults with R/R B cell precursor ALL.

Summary

Three ADCs have been approved for the treatment of various hematologic malignancies. We discuss the pertinent human trials that led to FDA approval. We include our perspectives about drug resistance, toxicities, and future development.
Literatur
1.
Zurück zum Zitat Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.
2.
Zurück zum Zitat Uhr JW. The 1984 Nobel Prize in medicine. Science. 1984;226(4678):1025–8.PubMed Uhr JW. The 1984 Nobel Prize in medicine. Science. 1984;226(4678):1025–8.PubMed
3.
Zurück zum Zitat Liu AY, et al. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A. 1987;84(10):3439–43.PubMedPubMedCentral Liu AY, et al. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A. 1987;84(10):3439–43.PubMedPubMedCentral
4.
Zurück zum Zitat Maloney DG, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188–95. Maloney DG, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188–95.
5.
Zurück zum Zitat Vose JM, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2000;18(6):1316–23.PubMed Vose JM, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2000;18(6):1316–23.PubMed
6.
Zurück zum Zitat Witzig TE, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17(12):3793–803.PubMed Witzig TE, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17(12):3793–803.PubMed
7.
Zurück zum Zitat Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5(2):147–59.PubMed Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5(2):147–59.PubMed
8.
Zurück zum Zitat Sievers EL, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678–84.PubMed Sievers EL, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678–84.PubMed
9.
Zurück zum Zitat Lee MD, et al. Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin.gamma.1I. J Am Chem Soc. 1987;109(11):3464–6. Lee MD, et al. Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin.gamma.1I. J Am Chem Soc. 1987;109(11):3464–6.
10.
Zurück zum Zitat Lee MD, et al. Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I. J Antibiot (Tokyo). 1989;42(7):1070–87. Lee MD, et al. Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I. J Antibiot (Tokyo). 1989;42(7):1070–87.
11.
Zurück zum Zitat Dedon PC, Salzberg AA, Xu J. Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry. 1993;32(14):3617–22.PubMed Dedon PC, Salzberg AA, Xu J. Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry. 1993;32(14):3617–22.PubMed
12.
Zurück zum Zitat Naito K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14(8):1436–43.PubMed Naito K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14(8):1436–43.PubMed
13.
Zurück zum Zitat Amico D, et al. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood. 2003;101(11):4589–97.PubMed Amico D, et al. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood. 2003;101(11):4589–97.PubMed
14.
Zurück zum Zitat Bhattacharyya B, Wolff J. Maytansine binding to the vinblastine sites of tubulin. FEBS Lett. 1977;75(1):159–62.PubMed Bhattacharyya B, Wolff J. Maytansine binding to the vinblastine sites of tubulin. FEBS Lett. 1977;75(1):159–62.PubMed
15.
Zurück zum Zitat Widdison WC, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem. 2006;49(14):4392–408.PubMed Widdison WC, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem. 2006;49(14):4392–408.PubMed
16.
Zurück zum Zitat Eaton JS, et al. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589–604.PubMedPubMedCentral Eaton JS, et al. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589–604.PubMedPubMedCentral
17.
Zurück zum Zitat Pettit GR, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc. 1987;109:6883–5. Pettit GR, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc. 1987;109:6883–5.
18.
Zurück zum Zitat Doronina SO, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–84.PubMed Doronina SO, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–84.PubMed
19.
Zurück zum Zitat Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65.PubMed Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65.PubMed
20.
Zurück zum Zitat Goldufsky J, et al. Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. J Med Microbiol. 2015;64(Pt 2):164–73.PubMedPubMedCentral Goldufsky J, et al. Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. J Med Microbiol. 2015;64(Pt 2):164–73.PubMedPubMedCentral
21.
Zurück zum Zitat Weldon JE, Pastan I. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin a for the treatment of cancer. FEBS J. 2011;278(23):4683–700.PubMedPubMedCentral Weldon JE, Pastan I. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin a for the treatment of cancer. FEBS J. 2011;278(23):4683–700.PubMedPubMedCentral
22.
Zurück zum Zitat Tendler MD, Korman S. ‘Refuin’: a non-cytotoxic carcinostatic compound proliferated by a thermophilic actinomycete. Nature. 1963;199:501.PubMed Tendler MD, Korman S. ‘Refuin’: a non-cytotoxic carcinostatic compound proliferated by a thermophilic actinomycete. Nature. 1963;199:501.PubMed
23.
Zurück zum Zitat Leimgruber W, et al. Isolation and characterization of anthramycin, a new antitumor antibiotic. J Am Chem Soc. 1965;87(24):5791–3.PubMed Leimgruber W, et al. Isolation and characterization of anthramycin, a new antitumor antibiotic. J Am Chem Soc. 1965;87(24):5791–3.PubMed
24.
Zurück zum Zitat Leimgruber W, Batcho AD, Schenker F. The structure of anthramycin. J Am Chem Soc. 1965;87(24):5793–5.PubMed Leimgruber W, Batcho AD, Schenker F. The structure of anthramycin. J Am Chem Soc. 1965;87(24):5793–5.PubMed
25.
Zurück zum Zitat Bose DS, et al. Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system. J Am Chem Soc. 1992;114(12):4939–41. Bose DS, et al. Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system. J Am Chem Soc. 1992;114(12):4939–41.
26.
Zurück zum Zitat Jenkins TC, et al. Structure of a covalent DNA minor groove adduct with a pyrrolobenzodiazepine dimer: evidence for sequence-specific interstrand cross-linking. J Med Chem. 1994;37(26):4529–37.PubMed Jenkins TC, et al. Structure of a covalent DNA minor groove adduct with a pyrrolobenzodiazepine dimer: evidence for sequence-specific interstrand cross-linking. J Med Chem. 1994;37(26):4529–37.PubMed
27.
Zurück zum Zitat Petrusek RL, et al. Reaction of anthramycin with DNA. Biological consequences of DNA damage in normal and xeroderma pigmentosum cell. J Biol Chem. 1982;257(11):6207–16.PubMed Petrusek RL, et al. Reaction of anthramycin with DNA. Biological consequences of DNA damage in normal and xeroderma pigmentosum cell. J Biol Chem. 1982;257(11):6207–16.PubMed
28.
Zurück zum Zitat Varki A, Angata T. Siglecs--the major subfamily of I-type lectins. Glycobiology. 2006;16(1):1R–27R.PubMed Varki A, Angata T. Siglecs--the major subfamily of I-type lectins. Glycobiology. 2006;16(1):1R–27R.PubMed
29.
Zurück zum Zitat Crocker PR, McMillan SJ, Richards HE. CD33-related siglecs as potential modulators of inflammatory responses. Ann N Y Acad Sci. 2012;1253:102–11.PubMed Crocker PR, McMillan SJ, Richards HE. CD33-related siglecs as potential modulators of inflammatory responses. Ann N Y Acad Sci. 2012;1253:102–11.PubMed
30.
Zurück zum Zitat Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood. 1983;62(1):124–32.PubMed Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood. 1983;62(1):124–32.PubMed
31.
Zurück zum Zitat Griffin JD, et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8(4):521–34.PubMed Griffin JD, et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8(4):521–34.PubMed
32.
Zurück zum Zitat Andrews RG, et al. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood. 1986;68(5):1030–5.PubMed Andrews RG, et al. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood. 1986;68(5):1030–5.PubMed
33.
Zurück zum Zitat Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med. 1989;169(5):1721–31.PubMed Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med. 1989;169(5):1721–31.PubMed
34.
Zurück zum Zitat Tanimoto M, et al. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989;3(5):339–48.PubMed Tanimoto M, et al. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989;3(5):339–48.PubMed
35.
Zurück zum Zitat Maniecki MB, et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 2012;131(10):2320–31.PubMed Maniecki MB, et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 2012;131(10):2320–31.PubMed
36.
Zurück zum Zitat Hernandez-Caselles T, et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol. 2006;79(1):46–58.PubMed Hernandez-Caselles T, et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol. 2006;79(1):46–58.PubMed
37.
Zurück zum Zitat Sievers EL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54.PubMed Sievers EL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54.PubMed
38.
Zurück zum Zitat Hamann PR, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem. 2002;13(1):40–6.PubMed Hamann PR, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem. 2002;13(1):40–6.PubMed
39.
Zurück zum Zitat Hamann PR, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47–58.PubMed Hamann PR, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47–58.PubMed
40.
Zurück zum Zitat Larson RA, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16(9):1627–36.PubMed Larson RA, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16(9):1627–36.PubMed
41.
Zurück zum Zitat Larson RA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–52.PubMed Larson RA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–52.PubMed
42.
Zurück zum Zitat Petersdorf SH, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.PubMedPubMedCentral Petersdorf SH, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.PubMedPubMedCentral
43.
Zurück zum Zitat Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–96.PubMedPubMedCentral Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–96.PubMedPubMedCentral
44.
Zurück zum Zitat Burnett AK, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–77.PubMed Burnett AK, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–77.PubMed
45.
Zurück zum Zitat Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–16.PubMed Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–16.PubMed
46.
Zurück zum Zitat Burnett AK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924–31.PubMed Burnett AK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924–31.PubMed
47.
Zurück zum Zitat Delaunay J, et al. Addition of Gemtuzumab Ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. Blood. 2011;118(21):79. Delaunay J, et al. Addition of Gemtuzumab Ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. Blood. 2011;118(21):79.
48.
Zurück zum Zitat Amadori S, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972–9.PubMed Amadori S, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972–9.PubMed
49.
Zurück zum Zitat Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221(4617):1285–8.PubMed Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221(4617):1285–8.PubMed
50.
Zurück zum Zitat Kartner N, et al. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 1985;316(6031):820–3.PubMed Kartner N, et al. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 1985;316(6031):820–3.PubMed
51.
Zurück zum Zitat Matsui H, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia. 2002;16(5):813–9.PubMed Matsui H, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia. 2002;16(5):813–9.PubMed
52.
Zurück zum Zitat Walter RB, et al. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood. 2003;102(4):1466–73.PubMed Walter RB, et al. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood. 2003;102(4):1466–73.PubMed
53.
Zurück zum Zitat Walter RB, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109(10):4168–70.PubMedPubMedCentral Walter RB, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109(10):4168–70.PubMedPubMedCentral
54.
Zurück zum Zitat Linenberger ML, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98(4):988–94.PubMed Linenberger ML, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98(4):988–94.PubMed
55.
Zurück zum Zitat Matsumoto T, et al. Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin. Leuk Lymphoma. 2012;53(7):1399–405.PubMed Matsumoto T, et al. Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin. Leuk Lymphoma. 2012;53(7):1399–405.PubMed
56.
Zurück zum Zitat Apostolidou E, et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res. 2003;27(10):887–91.PubMed Apostolidou E, et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res. 2003;27(10):887–91.PubMed
57.
Zurück zum Zitat Tsimberidou A, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003;27(10):893–7.PubMed Tsimberidou A, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003;27(10):893–7.PubMed
58.
Zurück zum Zitat Tsimberidou A, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003;97(6):1481–7.PubMed Tsimberidou A, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003;97(6):1481–7.PubMed
59.
Zurück zum Zitat Walter RB, et al. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood. 2004;103(11):4276–84.PubMed Walter RB, et al. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood. 2004;103(11):4276–84.PubMed
60.
Zurück zum Zitat Walter RB, et al. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood. 2005;106(10):3584–93.PubMedPubMedCentral Walter RB, et al. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood. 2005;106(10):3584–93.PubMedPubMedCentral
61.
Zurück zum Zitat Kurimoto M, et al. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. Leukemia. 2013;27(1):233–5.PubMed Kurimoto M, et al. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. Leukemia. 2013;27(1):233–5.PubMed
62.
Zurück zum Zitat Daver N, et al. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016;30(2):268–73.PubMed Daver N, et al. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016;30(2):268–73.PubMed
63.
Zurück zum Zitat Rosen DB, et al. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One. 2013;8(1):e53518.PubMedPubMedCentral Rosen DB, et al. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One. 2013;8(1):e53518.PubMedPubMedCentral
64.
Zurück zum Zitat Haag P, et al. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol. 2009;37(6):755–66.PubMed Haag P, et al. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol. 2009;37(6):755–66.PubMed
65.
Zurück zum Zitat Giles FJ, et al. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother. 2003;37(9):1182–5.PubMed Giles FJ, et al. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother. 2003;37(9):1182–5.PubMed
66.
Zurück zum Zitat Giles FJ, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.PubMed Giles FJ, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.PubMed
67.
Zurück zum Zitat Wadleigh M, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578–82.PubMed Wadleigh M, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578–82.PubMed
68.
Zurück zum Zitat Guffroy M, et al. Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in cynomolgus monkeys-mechanism and monitoring. Clin Cancer Res. 2017;23(7):1760–70.PubMed Guffroy M, et al. Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in cynomolgus monkeys-mechanism and monitoring. Clin Cancer Res. 2017;23(7):1760–70.PubMed
69.
Zurück zum Zitat McKoy JM, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604.PubMed McKoy JM, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604.PubMed
70.
Zurück zum Zitat Maniecki MB, et al. Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes? Leuk Res. 2011;35(6):e84–6.PubMed Maniecki MB, et al. Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes? Leuk Res. 2011;35(6):e84–6.PubMed
71.
Zurück zum Zitat McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma. 2002;2(Suppl 1):S35–9.PubMed McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma. 2002;2(Suppl 1):S35–9.PubMed
72.
Zurück zum Zitat Versluys B, et al. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood. 2004;103(5):1968.PubMed Versluys B, et al. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood. 2004;103(5):1968.PubMed
73.
Zurück zum Zitat Lannoy D, et al. Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report. J Clin Pharm Ther. 2006;31(4):389–92.PubMed Lannoy D, et al. Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report. J Clin Pharm Ther. 2006;31(4):389–92.PubMed
74.
Zurück zum Zitat Richardson PG, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Expert Rev Clin Pharmacol. 2018;11(2):113–24.PubMed Richardson PG, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Expert Rev Clin Pharmacol. 2018;11(2):113–24.PubMed
75.
Zurück zum Zitat Jawad M, et al. Targeting of CD34+CD38- cells using gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute myeloid Leukaemia. BMC Cancer. 2012;12:431.PubMedPubMedCentral Jawad M, et al. Targeting of CD34+CD38- cells using gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute myeloid Leukaemia. BMC Cancer. 2012;12:431.PubMedPubMedCentral
76.
Zurück zum Zitat Rosen DB, et al. Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leuk Res. 2012;36(7):900–4.PubMed Rosen DB, et al. Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leuk Res. 2012;36(7):900–4.PubMed
77.
Zurück zum Zitat Lapusan S, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Investig New Drugs. 2012;30(3):1121–31. Lapusan S, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Investig New Drugs. 2012;30(3):1121–31.
78.
Zurück zum Zitat Kung Sutherland MS, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455–63.PubMed Kung Sutherland MS, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455–63.PubMed
79.
Zurück zum Zitat Stein EM, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018;131(4):387–96.PubMedPubMedCentral Stein EM, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018;131(4):387–96.PubMedPubMedCentral
80.
Zurück zum Zitat Stein H, et al. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer. 1982;30(4):445–59.PubMed Stein H, et al. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer. 1982;30(4):445–59.PubMed
81.
Zurück zum Zitat Durkop H, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell. 1992;68(3):421–7.PubMed Durkop H, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell. 1992;68(3):421–7.PubMed
82.
Zurück zum Zitat Schwab U, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65–7.PubMed Schwab U, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65–7.PubMed
83.
Zurück zum Zitat Ellis TM, et al. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol. 1993;151(5):2380–9.PubMed Ellis TM, et al. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol. 1993;151(5):2380–9.PubMed
84.
Zurück zum Zitat Stein H, et al. Hodgkin and Sternberg-reed cells contain antigens specific to late cells of granulopoiesis. Int J Cancer. 1982;29(3):283–90.PubMed Stein H, et al. Hodgkin and Sternberg-reed cells contain antigens specific to late cells of granulopoiesis. Int J Cancer. 1982;29(3):283–90.PubMed
85.
Zurück zum Zitat Feller AC, Sterry W. Large cell anaplastic lymphoma of the skin. Br J Dermatol. 1989;121(5):593–602.PubMed Feller AC, Sterry W. Large cell anaplastic lymphoma of the skin. Br J Dermatol. 1989;121(5):593–602.PubMed
86.
Zurück zum Zitat Hu S, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715–24.PubMedPubMedCentral Hu S, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715–24.PubMedPubMedCentral
87.
Zurück zum Zitat Kaudewitz P, et al. Monoclonal antibody patterns in lymphomatoid papulosis. Dermatol Clin. 1985;3(4):749–57.PubMed Kaudewitz P, et al. Monoclonal antibody patterns in lymphomatoid papulosis. Dermatol Clin. 1985;3(4):749–57.PubMed
88.
Zurück zum Zitat Blatt K, et al. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood. 2015;126(26):2832–41.PubMedPubMedCentral Blatt K, et al. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood. 2015;126(26):2832–41.PubMedPubMedCentral
89.
Zurück zum Zitat Gerli R, et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol. 2000;164(8):4399–407.PubMed Gerli R, et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol. 2000;164(8):4399–407.PubMed
90.
Zurück zum Zitat Ihn H, et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol. 2000;27(3):698–702.PubMed Ihn H, et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol. 2000;27(3):698–702.PubMed
91.
Zurück zum Zitat McMillan SA, et al. Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis. Acta Neurol Scand. 2000;101(4):239–43.PubMed McMillan SA, et al. Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis. Acta Neurol Scand. 2000;101(4):239–43.PubMed
92.
Zurück zum Zitat Barbieri A, et al. Characterization of CD30/CD30L(+) cells in peripheral blood and synovial fluid of patients with rheumatoid arthritis. J Immunol Res. 2015;2015:729654.PubMedPubMedCentral Barbieri A, et al. Characterization of CD30/CD30L(+) cells in peripheral blood and synovial fluid of patients with rheumatoid arthritis. J Immunol Res. 2015;2015:729654.PubMedPubMedCentral
93.
Zurück zum Zitat Shinoda K, et al. Requirement of CD30 expression on CD4 T cells in the pathogenesis of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2016;291:39–45.PubMed Shinoda K, et al. Requirement of CD30 expression on CD4 T cells in the pathogenesis of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2016;291:39–45.PubMed
94.
Zurück zum Zitat Gerli R, et al. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol. 2001;22(2):72–7.PubMed Gerli R, et al. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol. 2001;22(2):72–7.PubMed
95.
Zurück zum Zitat Younes A, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.PubMed Younes A, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.PubMed
96.
Zurück zum Zitat •• Younes A, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9 This important trial studied Bv in R/R HL patients who failed autoSCT and contributed to the FDA approval of Bv for R/R HL.PubMedPubMedCentral •• Younes A, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9 This important trial studied Bv in R/R HL patients who failed autoSCT and contributed to the FDA approval of Bv for R/R HL.PubMedPubMedCentral
97.
Zurück zum Zitat Chen R, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–6.PubMedPubMedCentral Chen R, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–6.PubMedPubMedCentral
98.
Zurück zum Zitat Pro B, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6.PubMed Pro B, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6.PubMed
99.
Zurück zum Zitat Moskowitz CH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62.PubMed Moskowitz CH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62.PubMed
100.
Zurück zum Zitat Younes A, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56.PubMed Younes A, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56.PubMed
101.
Zurück zum Zitat Connors JM, et al. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood. 2017;130(11):1375–7.PubMedPubMedCentral Connors JM, et al. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood. 2017;130(11):1375–7.PubMedPubMedCentral
102.
Zurück zum Zitat Connors JM, et al. Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–44.PubMed Connors JM, et al. Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–44.PubMed
103.
Zurück zum Zitat LaCasce AS, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;126(23):3982. LaCasce AS, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;126(23):3982.
104.
Zurück zum Zitat O’Connor OA, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19(2):257–66.PubMed O’Connor OA, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19(2):257–66.PubMed
105.
Zurück zum Zitat Horwitz SM, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–100.PubMedPubMedCentral Horwitz SM, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–100.PubMedPubMedCentral
106.
Zurück zum Zitat Mehra T, et al. Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome. JAMA Dermatol. 2015;151(1):73–7.PubMed Mehra T, et al. Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome. JAMA Dermatol. 2015;151(1):73–7.PubMed
107.
Zurück zum Zitat Kim YH, et al. Phase II investigator-initiated study of Brentuximab Vedotin in mycosis Fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–8.PubMedPubMedCentral Kim YH, et al. Phase II investigator-initiated study of Brentuximab Vedotin in mycosis Fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–8.PubMedPubMedCentral
108.
Zurück zum Zitat Duvic M, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–65.PubMedPubMedCentral Duvic M, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–65.PubMedPubMedCentral
109.
Zurück zum Zitat Prince HM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–66.PubMed Prince HM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–66.PubMed
110.
Zurück zum Zitat Jacobsen ED, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–402.PubMed Jacobsen ED, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–402.PubMed
111.
Zurück zum Zitat DeFilipp Z, et al. Phase I trial of brentuximab vedotin for steroid-refractory chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018. DeFilipp Z, et al. Phase I trial of brentuximab vedotin for steroid-refractory chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018.
112.
Zurück zum Zitat Chen R, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14(6):1376–84.PubMedPubMedCentral Chen R, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14(6):1376–84.PubMedPubMedCentral
113.
Zurück zum Zitat Straus DJ et al. Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma. J Clin Oncol. 2018;36(Suppl). Straus DJ et al. Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma. J Clin Oncol. 2018;36(Suppl).
114.
Zurück zum Zitat Hershman DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.PubMed Hershman DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.PubMed
115.
Zurück zum Zitat Jalan P, et al. Brentuximab associated progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg. 2012;114(10):1335–7.PubMed Jalan P, et al. Brentuximab associated progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg. 2012;114(10):1335–7.PubMed
116.
Zurück zum Zitat Urru SA, et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report. Drugs R D. 2014;14(1):9–11.PubMedPubMedCentral Urru SA, et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report. Drugs R D. 2014;14(1):9–11.PubMedPubMedCentral
117.
Zurück zum Zitat Carson KR, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120(16):2464–71.PubMedPubMedCentral Carson KR, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120(16):2464–71.PubMedPubMedCentral
118.
Zurück zum Zitat Gandhi MD, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood. 2014;123(18):2895–7.PubMedPubMedCentral Gandhi MD, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood. 2014;123(18):2895–7.PubMedPubMedCentral
119.
Zurück zum Zitat Diefenbach CS, et al. Safety and efficacy of combination of brentuximab vedotin and Nivolumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer research group (E4412). Hematol Oncol. 2017;128(22):1106. Diefenbach CS, et al. Safety and efficacy of combination of brentuximab vedotin and Nivolumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer research group (E4412). Hematol Oncol. 2017;128(22):1106.
120.
Zurück zum Zitat Herrera AF, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–94.PubMedPubMedCentral Herrera AF, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–94.PubMedPubMedCentral
121.
Zurück zum Zitat Doody GM, et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995;269(5221):242–4.PubMed Doody GM, et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995;269(5221):242–4.PubMed
122.
Zurück zum Zitat Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev. 2009;230(1):128–43.PubMed Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev. 2009;230(1):128–43.PubMed
123.
Zurück zum Zitat Vaickus L, Ball ED, Foon KA. Immune markers in hematologic malignancies. Crit Rev Oncol Hematol. 1991;11(4):267–97.PubMed Vaickus L, Ball ED, Foon KA. Immune markers in hematologic malignancies. Crit Rev Oncol Hematol. 1991;11(4):267–97.PubMed
124.
Zurück zum Zitat Raponi S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098–107.PubMed Raponi S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098–107.PubMed
125.
Zurück zum Zitat Piccaluga PP, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52(2):325–7.PubMed Piccaluga PP, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52(2):325–7.PubMed
126.
Zurück zum Zitat Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol. 1995;154(9):4466–75.PubMed Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol. 1995;154(9):4466–75.PubMed
127.
Zurück zum Zitat DiJoseph JF, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807–14.PubMed DiJoseph JF, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807–14.PubMed
128.
Zurück zum Zitat Advani A, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085–93.PubMed Advani A, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085–93.PubMed
129.
Zurück zum Zitat Ogura M, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8):1840–5.PubMed Ogura M, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8):1840–5.PubMed
130.
Zurück zum Zitat Goy A, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016;174(4):571–81.PubMed Goy A, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016;174(4):571–81.PubMed
131.
Zurück zum Zitat Ogura M, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103(5):933–8.PubMed Ogura M, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103(5):933–8.PubMed
132.
Zurück zum Zitat Fayad L, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–83.PubMedPubMedCentral Fayad L, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–83.PubMedPubMedCentral
133.
Zurück zum Zitat Takeshita A, et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia. 2009;23(7):1329–36.PubMed Takeshita A, et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia. 2009;23(7):1329–36.PubMed
134.
Zurück zum Zitat Wagner-Johnston ND, et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(10):2863–9.PubMed Wagner-Johnston ND, et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(10):2863–9.PubMed
135.
Zurück zum Zitat Ogura M, et al. Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2016;22(19):4807–16.PubMed Ogura M, et al. Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2016;22(19):4807–16.PubMed
136.
Zurück zum Zitat Sangha R, et al. Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. J Drug Assess. 2017;6(1):10–7.PubMedPubMedCentral Sangha R, et al. Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. J Drug Assess. 2017;6(1):10–7.PubMedPubMedCentral
137.
Zurück zum Zitat Dang NH, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2017. Dang NH, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2017.
138.
Zurück zum Zitat •• Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–11 This important phase II trial led to promising results in B-ALL, contributing to the basis for FDA approval in a disease where there are limited options after relapse.PubMed •• Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–11 This important phase II trial led to promising results in B-ALL, contributing to the basis for FDA approval in a disease where there are limited options after relapse.PubMed
139.
Zurück zum Zitat Kantarjian H, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–36.PubMedPubMedCentral Kantarjian H, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–36.PubMedPubMedCentral
140.
Zurück zum Zitat DeAngelo DJ, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1(15):1167–80.PubMedPubMedCentral DeAngelo DJ, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1(15):1167–80.PubMedPubMedCentral
141.
Zurück zum Zitat Kantarjian HM, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.PubMedPubMedCentral Kantarjian HM, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.PubMedPubMedCentral
142.
Zurück zum Zitat Jabbour E, et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015;90(3):193–6.PubMedPubMedCentral Jabbour E, et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015;90(3):193–6.PubMedPubMedCentral
143.
Zurück zum Zitat Kantarjian H, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240–8.PubMed Kantarjian H, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240–8.PubMed
144.
Zurück zum Zitat Stephan JP, et al. Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem. 2008;19(8):1673–83.PubMed Stephan JP, et al. Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem. 2008;19(8):1673–83.PubMed
145.
Zurück zum Zitat Polson AG, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin’s lymphoma. Leukemia. 2010;24(9):1566–73.PubMed Polson AG, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin’s lymphoma. Leukemia. 2010;24(9):1566–73.PubMed
146.
Zurück zum Zitat Kato J, et al. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma. Oncoimmunology. 2012;1(9):1469–75.PubMedPubMedCentral Kato J, et al. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma. Oncoimmunology. 2012;1(9):1469–75.PubMedPubMedCentral
147.
Zurück zum Zitat Kato J, et al. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. Leuk Res. 2013;37(1):83–8.PubMed Kato J, et al. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. Leuk Res. 2013;37(1):83–8.PubMed
148.
Zurück zum Zitat Takeshita A, et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol. 2009;146(1):34–43.PubMed Takeshita A, et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol. 2009;146(1):34–43.PubMed
149.
Zurück zum Zitat Kebriaei P, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449–56.PubMedPubMedCentral Kebriaei P, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449–56.PubMedPubMedCentral
150.
Zurück zum Zitat Li D, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther. 2013;12(7):1255–65.PubMed Li D, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther. 2013;12(7):1255–65.PubMed
151.
Zurück zum Zitat Fuh FK, et al. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. Br J Pharmacol. 2017;174(8):628–40.PubMedPubMedCentral Fuh FK, et al. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. Br J Pharmacol. 2017;174(8):628–40.PubMedPubMedCentral
152.
Zurück zum Zitat Abuhay M, et al. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity. Cancer Immunol Immunother. 2016;65(10):1169–75.PubMed Abuhay M, et al. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity. Cancer Immunol Immunother. 2016;65(10):1169–75.PubMed
153.
Zurück zum Zitat Kantarjian HM, et al. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018;124(10):2151–60.PubMed Kantarjian HM, et al. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018;124(10):2151–60.PubMed
154.
Zurück zum Zitat Kreitman RJ, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018;131(21):2331–4.PubMed Kreitman RJ, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018;131(21):2331–4.PubMed
155.
Zurück zum Zitat Kreitman RJ, et al. Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: results of a pivotal international study. J Clin Oncol. 2018;36. Kreitman RJ, et al. Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: results of a pivotal international study. J Clin Oncol. 2018;36.
156.
Zurück zum Zitat Advani RH, et al. Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2017;23(5):1167–76.PubMed Advani RH, et al. Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2017;23(5):1167–76.PubMed
157.
Zurück zum Zitat Morschhauser F, et al. Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2014;124(21):4457. Morschhauser F, et al. Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2014;124(21):4457.
158.
Zurück zum Zitat Trneny M, et al. A phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018. Trneny M, et al. A phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018.
159.
Zurück zum Zitat Kahl BS, et al. Encouraging early results from the first in-human clinical trial of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory B-cell lineage non-Hodgkin lymphoma. Blood. 2017;130(Suppl 1):187. Kahl BS, et al. Encouraging early results from the first in-human clinical trial of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory B-cell lineage non-Hodgkin lymphoma. Blood. 2017;130(Suppl 1):187.
160.
Zurück zum Zitat Ryan MC, et al. Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. Blood. 2017;130(18):2018–26.PubMedPubMedCentral Ryan MC, et al. Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. Blood. 2017;130(18):2018–26.PubMedPubMedCentral
161.
Zurück zum Zitat Horwitz SM, et al. Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel Pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma. Blood. 2018;130(Suppl 1):1510. Horwitz SM, et al. Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel Pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma. Blood. 2018;130(Suppl 1):1510.
162.
Zurück zum Zitat Sawas A, et al. A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. J Clin Oncol. 2016;34(15_suppl):7549. Sawas A, et al. A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. J Clin Oncol. 2016;34(15_suppl):7549.
163.
Zurück zum Zitat Stathis A, et al. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Investig New Drugs. 2018:1–8. Stathis A, et al. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Investig New Drugs. 2018:1–8.
164.
Zurück zum Zitat Kelly KR, et al. Indatuximab Ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: clinical activity in patients with relapsed/refractory multiple myeloma. Blood. 2016;128(22):4486. Kelly KR, et al. Indatuximab Ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: clinical activity in patients with relapsed/refractory multiple myeloma. Blood. 2016;128(22):4486.
Metadaten
Titel
Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies
verfasst von
Helen Ma
Ahmed Sawas
Publikationsdatum
25.10.2018
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 6/2018
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-018-0485-3

Weitere Artikel der Ausgabe 6/2018

Current Hematologic Malignancy Reports 6/2018 Zur Ausgabe

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities

T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Breast Implant-Associated Anaplastic Large Cell Lymphoma

CART and Immunotherapy (M Ruella, Section Editor)

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Online and Social Media Resources for Patients with MDS

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.